Briefing
Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC).
Time to confirmed deterioration in physical functioning, role functioning, and global health status/quality of life showed no evidence of a difference between atezolizumab and placebo. More than 90% of patients in both arms reported little or no treatment side-effect burden through cycle 11. The abstract concludes ctDNA-guided adjuvant atezolizumab improved DFS and OS without negatively affecting patient-reported quality of life.
- n: 250 ctDNA-positive patients randomized (167 atezolizumab, 83 placebo)
- Assay: not named in the abstract